期刊
HUMAN MOLECULAR GENETICS
卷 21, 期 5, 页码 1138-1144出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddr542
关键词
-
资金
- Medivation
- GSK
- Pfizer
- National Institutes of Health [AG028679, NS062787]
- Alzheimer's Association [NIRG-09-132727]
- Dr Robert M. Kohrman Memorial Fund
In Alzheimer disease (AD), amyloid- (A) oligomer is suggested to play a critical role in imitating neurodegeneration, although its pathogenic mechanism remains to be determined. Recently, the cellular prion protein (PrPC) has been reported to be an essential co-factor in mediating the neurotoxic effect of A oligomer. However, these previous studies focused on the synaptic plasticity in either the presence or the absence of PrPC and no study to date has reported whether PrPC is required for the neuronal cell death, the most critical element of neurodegeneration in AD. Here, we show that Prnp(/) mice are resistant to the neurotoxic effect of A oligomer in vivo and in vitro. Furthermore, application of an anti-PrPC antibody or PrPC peptide prevents A oligomer-induced neurotoxicity. These findings are the first to demonstrate that PrPC is required for A oligomer-induced neuronal cell death, the pathology essential to cognitive loss.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据